透皮给药研究的新进展

透皮给药安全可控，是无创给药的新途径，有着广阔的市场前景。现有的透皮药物限于小分子和低浓度，角质层屏障使大多数药物难以通过或难以达到有效浓度和有效速率。透皮给药的关键在于促进药物渗透，使药物透皮吸收进毛细血管。促渗手段有：使用化学促渗剂；对药物进行化学修饰制成前体药物；使用物理方法；将药物载入载体。这些方法的原理大致分为三种：改变角质层结构；外力驱动药物；将药物进行修饰或包裹。简要地介绍了增强药物透皮的物理方法和载体方法研究的新进展。     

3-硝基酪氨酸在细菌内毒素诱导大鼠血管低反应性中的介导作用

目的：观察3-硝基酪氨酸（3-NT）对感染性休克大鼠血管低反应性的介导作用及抗氧化剂对此的治疗效果。 方法： 40只雄性SD大鼠随机分成空白对照组(n=10); LPS休克组（LPS 15 mg·kg-1 iv, n=10）; 尿酸(UA)治疗组（注射LPS 1 h后200 mg·kg-1 ip, n=10）; N-乙酰-5-甲氧基色胺（melatonin）治疗组（注射LPS 1 h后10 mg·kg-1 ip, n=10）。空白对照组及注射LPS 6 h后各组动物，静注去氧肾上腺素（PE, 0.5-2.5 μg·kg-1）,记录注药后MAP的增加百分比。所有in vivo实验结束后取大鼠胸主动脉环作张力实验,，建立PE的剂量-反应曲线并计算相应的Emax、EC50值。注射LPS 6 h后检测各组动物血浆丙二醛（MDA）、硝酸盐/亚硝酸盐（nitrate/nitrite）与3-NT的含量。 结果： 静脉注射PE后，休克组动物MAP的平均增长率与对照组相比显著降低至54.60%（P<0.01）；而UA组、melatonin组MAP对PE反应的增长率较之休克组分别增高了37.70%、40.03%(P<0.05)。休克组大鼠胸主动脉环对PE的反应［(Emax，35.30%±9.80%； EC50， (15.70±4.50)nmol/L］与对照组相比有显著差异［（Emax，100%； EC50， (4.71±2.04) nmol/L, P<0.05］，经UA、melatonin治疗后血管反应性有显著改善(P<0.05)。尿酸、N-乙酰-5-甲氧基色胺治疗组的血浆MDA、硝酸盐/亚硝酸盐和3-NT的浓度也明显低于休克组(P<0.05)。 结论： 3-NT是感染性休克血管低反应的重要介导因子，抗氧化剂通过清除氧自由基，减少脂质过氧化物的形成、抑制体内NO的过量合成及有效清除3-NT，从而改善α-肾上腺素能受体介导的血管低反应性，对临床感染性休克病人的治疗可能有积极作用。     

一个遗传性非综合征型耳聋家系的突变分析

目的分析一个遗传性非综合征型耳聋家系的突变，并探讨缝隙连接蛋白beta2(gap junction protein beta 2，GJB2)基因235delC突变是否会加重线粒体A1555G突变导致的非综合征型耳聋症状。方法对一个母系遗传性非综合征型耳聋核心家系72个成员取外周血提取DNA，经聚合酶链反应扩增后，利用Alw26Ⅰ限制性内切酶酶切及直接测序验证，对其线粒体DNA突变进行研究；利用ApaⅠ限制性内切酶酶切及直接测序验证，筛查核心家系中GJB2基因235delC突变情况，并对GJB2基因235delC和线粒体A1555G突变的关系进行研究。结果在27名母系成员中均发现具有线粒体A1555G突变，呈母系遗传；具有耳聋表型的为21人(77．8％)，家族外显率高；所筛查的包括配偶在内的72名个体中，仅3例具有GJB2基因235delC杂合子突变，且均出现在母系成员中，但3例的耳聋表型却不同。结论线粒体A1555G突变是本家系耳聋遗传易感性的基础，在该家系中GJB2基因的235delC杂合子突变未加重线粒体A1555G突变导致的非综合征型耳聋。     

Sequence Comparison of Avian Infectious Bronchitis Virus S1 Glycoproteins of the Florida Serotype and Five Variant Isolates from Georgia and California

The infectious bronchitis virus (IBV) spike glycoprotein S1 subunit is required to initiate infection and contains virus-neutralizing and serotype-specific epitope(s). Reported are the S1 gene nucleotide and predicted amino acid sequences for the Florida 18288 strain and isolates GA-92, CV-56b, CV-9437, CV-1686, and 1013. These sequences were compared with previously published gene sequences of IBV strains, and phylogenetic relationships are reported. The S1 amino acid sequence of Florida 18288 was 94.9% similar to the Connecticut strain, and GA-92 was 92.8% similar to the Arkansas 99 strain. S1 amino acid sequences of the California variants, CV-56b, CV-9437, and CV-1686, were 97.6–99.3% similar to one another and only 76.6%–76.8% similar to the Arkansas-type strains. Isolate 1013, also from California, was 84.0% similar to Ark DPI and 77.9% similar to CV-56b. When comparing 19 viruses isolated from the United States, sequence variations were observed between amino acids 55–96, 115–149, 255–309, and 378–395. Similar regions are reported to be involved in virus-neutralizing and/or serotype-specific epitopes. These data demonstrate that variant IBV strains continue to emerge, and unique variants may circulate among poultry in geographically isolated areas. This revised version was published online in July 2006 with corrections to the Cover Date.     

多维分层反馈模式在医院内部质量评价中的应用效果

目的探讨多维分层反馈模式在医院内部质量评价中的应用效果。方法选择江苏省盐城市某三甲综合医院为样本医院,以职能部门、临床科室、医技科室共89个考核单元为研究对象,开展医院内部质量评价活动,应用多维分层理念建立质评反馈模式。结果应用多维分层反馈模式后,办公室、医务科、沟通办等职能部门月度质评现场管理成绩均有所提升（P＜0.05）;职能部门（台账资料）、临床医疗、医技科室及护理单元季度质评成绩均有所提高（P＜0.05）;危化品、不良事件、便携式血糖仪、知情同意及时间管理等专项质评追踪合格率均显著提高（P＜0.001）。结论将质评机制引入医院并形成科学化、常态化管理,是对外部评审的重要补充。而多维分层反馈模式的建立,有效地促进了部门、科室间的相互协作,提升了职能部门的管理成效,提高了医院整体的质量管理效能。     

OA学术期刊的出版规范及其版权管理

【目的】 勘察国际OA期刊的OA实践及其期刊政策声明,为我国OA期刊建设提供借鉴。【方法】 以DOAJ图情类期刊为研究对象,调查并分析期刊的出版形式如发行媒介、出版周期、收费情况等,以及存档政策、许可条款、OA模式等版权管理政策。【结果】 揭示OA期刊在出版频率、APC、OA模式方面出现的新形式、新模式,分析OA期刊在可访问性、透明性和开放性方面存在的问题。【结论】 OA已经成为学术期刊发展的必然方向,在版权管理方面仍处在初级阶段,认证环节较为混乱,现阶段处于多模式探索尝试阶段;OA期刊的出版管理应在保持适度灵活性的同时,着力加强规范建设。     

21世纪老年医学伦理学之探讨

21世纪人类全面进入人口老龄化,我国也进入了人口老年型国家的行列。文章叙述了21世纪我国老年人的特点,制定了衡量老年人生活质量的指标,并对提高老年人生活质量的对策,实现健康老龄化进行了医学伦理学方面的探讨。     

Guidelines for the diagnosis,treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli

The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Sixteen clinical questions were proposed from the perspective of current clinical practice and translated into research questions using PICO (population, intervention, comparator, and outcomes) format to collect and synthesize relevant evidence to inform corresponding recommendations. The grading of recommendations, assessment, development and evaluation (GRADE) approach was used to evaluate the quality of evidence, benefit and risk profile of corresponding interventions and formulate recommendations or suggestions. Evidence extracted from systematic reviews and randomized controlled trials (RCTs) was considered preferentially for treatment-related clinical questions. Observational studies, non-controlled studies, and expert opinions were considered as supplementary evidence in the absence of RCTs. The strength of recommendations was classified as strong or conditional (weak). The evidence informing recommendations derives from studies worldwide, while the implementation suggestions combined the Chinese experience. The target audience of this guideline is clinician and related professionals involved in management of infectious diseases.     

Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β-catenin pathway in the myocardium of mice after myocardial infarction

Myocardial infarction (MI) is one of the diseases with high fatality rate. Berberine (BBR) is a monomer compound with various biological functions. And some studies have confirmed that BBR plays an important role in alleviating cardiomyocyte injury after MI. However, the specific mechanism is unclear. In this study, we induced a model of MI by ligation of the left anterior descending coronary artery and we surprisingly found that BBR significantly improved ventricular remodeling, with a minor inflammatory and oxidative stress injury, and stronger angiogenesis. Moreover, BBR inhibited the secretion of Wnt5a/β-catenin pathway in macrophages after MI, thus promoting the differentiation of macrophages into M2 type. In summary, BBR effectively improved cardiac function of mice after MI, and the potential protective mechanism was associated with the regulation of inflammatory responses and the inhibition of macrophage Wnt5a/β-catenin pathway in the infarcted heart tissues. Importantly, these findings supported BBR as an effective cardioprotective drug after MI.